Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease
TOKYO, Apr 20, 2021 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. today…
Instruct3D Strengthens Additive Build Intelligence Message Following ICAM 2026
Otto Group and Sereact Bring NVIDIA-Powered Physical AI to Returns Processing